Home > Organization > Division of Functional Imaging
Group for Innovative Diagnostic and Therapeutic DeviceDivision of Functional Imaging
News
- Sep. 16, 2022
- Update member list
- Nov. 5, 2019
- Update member list
- Oct. 3, 2019
- Dr. Fujii, the chief of Division of Functional Imaging, was invited as a symposiast to the 9th Aslla Symposium
- Sep. 1, 2019
- The updated PET imaging site qualification program started.
- Jul. 4, 2019
- Dr. Fujii, the chief of Division of Functional Imaging, delivered a special lecture at the 56th Annual Meeting on Radioisotopes and Radiation Researches.
- Jun. 22, 2019
- The research activity of Division of Functional Imaging was highlighted at SNMMI 2019
- Mar. 27, 2019
- Dr. Fujii, the chief of Division of Functional Imaging, delivered an invited lecture at the symposium celebrating the opening of a new building of Show-Chwan Memorial Hospital in Taiwan
- Feb. 22, 2019
- Training course of Nuclear Medicine will be held between December 9th and 13th, 2019 based on the agreement between domestic nuclear medicine consortium in Japan and International Atomic Energy Agency (IAEA)
- Feb. 16, 2019
- “Zir-Net” Association started
- Our division is actively investigating imaging technologies to visualize functional aspects of tumor lesions in order to establish minimally invasive individualized therapeutic strategies. We are engaged in, especially, nuclear medicine tests, magnetic resonance imaging (MRI) tests, optical imaging tests and their fusion methods, using most advanced imaging devices equipped in our division.
- As for nuclear medicine tests, we are developing radioactive tumor-avid molecular probes. RGD probes that show high affinity to integrin appeared in tumor tissues and liposomes encapsulating radionuclides are representative ones. Currently, theranostics are topics in this research field. In theranostics, tumor lesions are detected by radiopharmaceuticals labeled by diagnostic radionuclides. Then, these tumor lesions are treated by compounds labeled by therapeutic radionuclides such as better emitters. Now we are also actively investigating radionuclide therapy using alpha emitters such as At-211 and Ac-225.
- As for MRI tests, we are studying unique application of super-paramagnetic iron oxide contrast agents. We experimentally demonstrated that irradiated liver tissues could be depicted with good contrast to non-irradiated areas using these iron compounds. Now, we are studying to optimize radiotherapy for hepatic tumors based on our experimental results.
- By using MRI technology, metabolic information of living bodies can be observed in the form of spectrum. We are applying this technology called MRS to the evaluation of metabolism of patients suffering from cancer. We expect that metabolic information of cancer survivors and super-responders obtained by MRS would be useful to the development of new cancer management strategies.
- As for optical imaging, we are studying clinical application of over thousand nanometer-near infrared lights imaging tests. As this light with long wavelength shows excellent tissue permeability, we are investigating tomographic imaging of cancer patients using this light.
- We are also engaged in clinical studies using artificial intelligence to improve diagnostic accuracy of imaging tests.
Links.
- Japan Radiological Society (Link to External Site.)
- Japanese Society of Nuclear Medicine (Link to External Site.)
- The Pharmaceutical Society of Japan (Link to External Site.)
- Japanese Society for Magnetic Resonance in Medicine (Link to External Site.)
- Japanese Society for Molecular Imaging (Link to External Site.)
- Japanese Society for Sentinel Node Navigation Surgery (Link to External Site.)
